Wai Yuen Tong Medicine Holdings Limited (HKG:0897)
Hong Kong · Delayed Price · Currency is HKD 0.3200
+0.0200 (6.67%)
Jul 31, 2026, 3:51 PM HKT
HKG:0897 Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 683.44 | 745.3 | 783.88 | 723.6 | 1,391 | |
Revenue Growth | -8.30% | -4.92% | 8.33% | -47.99% | 25.52% |
Cost of Revenue | 321.51 | 368.85 | 389.07 | 381.24 | 817.26 |
Gross Profit | 361.93 | 376.45 | 394.81 | 342.36 | 574.15 |
Selling, General & Admin | 378.99 | 408.3 | 354.98 | 331.52 | 499.2 |
Operating Expenses | 377.82 | 423.36 | 353.93 | 337.37 | 504.58 |
Operating Income | -15.89 | -46.91 | 40.88 | 4.99 | 69.58 |
Interest Expense | -17.59 | -28.16 | -40.79 | -29.51 | -95.7 |
Interest & Investment Income | 39.9 | 46.21 | 48.24 | 47.13 | 25.35 |
Earnings From Equity Investments | 1.57 | 1.05 | 2.53 | 2.95 | 1.57 |
Currency Exchange Gain (Loss) | 0.58 | -0.5 | -2.63 | -3.71 | 6.97 |
Other Non Operating Income (Expenses) | 6.42 | 5.98 | 7.91 | 5.06 | 55.29 |
EBT Excluding Unusual Items | 14.99 | -22.32 | 56.14 | 26.92 | 63.06 |
Gain (Loss) on Sale of Investments | 0.08 | -4.84 | -12.83 | -11.6 | -78.07 |
Gain (Loss) on Sale of Assets | 0.03 | 15.17 | 29.5 | -1.48 | 1.81 |
Asset Writedown | -11.47 | 14.2 | -86.48 | -20.13 | -80.62 |
Legal Settlements | - | - | - | - | 48.57 |
Other Unusual Items | - | 1.86 | 0.04 | 0.39 | -2.06 |
Pretax Income | 3.63 | 4.08 | -13.63 | -5.91 | -47.3 |
Income Tax Expense | -0.45 | -3.02 | -6.36 | -13.32 | 40.52 |
Earnings From Continuing Operations | 4.08 | 7.09 | -7.27 | 7.41 | -87.82 |
Earnings From Discontinued Operations | - | - | 11.32 | -4.07 | - |
Net Income to Company | 4.08 | 7.09 | 4.05 | 3.35 | -87.82 |
Minority Interest in Earnings | -0.08 | 0.01 | -19.4 | -23.86 | -21.09 |
Net Income | 3.99 | 7.1 | -15.36 | -20.52 | -108.91 |
Net Income to Common | 3.99 | 7.1 | -15.36 | -20.52 | -108.91 |
Net Income Growth | -43.77% | - | - | - | - |
Shares Outstanding (Basic) | 1,125 | 1,126 | 1,181 | 1,216 | 1,232 |
Shares Outstanding (Diluted) | 1,125 | 1,126 | 1,181 | 1,216 | 1,232 |
Shares Change | -0.08% | -4.70% | -2.87% | -1.25% | - |
EPS (Basic) | 0.00 | 0.01 | -0.01 | -0.02 | -0.09 |
EPS (Diluted) | 0.00 | 0.01 | -0.01 | -0.02 | -0.09 |
EPS Growth | -43.74% | - | - | - | - |
Free Cash Flow | 56.94 | 75.16 | 157.04 | 134.89 | 143.07 |
Free Cash Flow Per Share | 0.05 | 0.07 | 0.13 | 0.11 | 0.12 |
Dividend Per Share | - | - | 0.030 | - | - |
Dividend Growth | - | - | - | - | - |
Gross Margin | 52.96% | 50.51% | 50.37% | 47.31% | 41.26% |
Operating Margin | -2.33% | -6.29% | 5.21% | 0.69% | 5.00% |
Profit Margin | 0.58% | 0.95% | -1.96% | -2.83% | -7.83% |
Free Cash Flow Margin | 8.33% | 10.08% | 20.03% | 18.64% | 10.28% |
EBITDA | 17.64 | -13.56 | 92.58 | 59.6 | 130.58 |
EBITDA Margin | 2.58% | -1.82% | 11.81% | 8.24% | 9.38% |
D&A For EBITDA | 33.53 | 33.35 | 51.7 | 54.61 | 61 |
EBIT | -15.89 | -46.91 | 40.88 | 4.99 | 69.58 |
EBIT Margin | -2.32% | -6.29% | 5.21% | 0.69% | 5.00% |